Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in treatment and patient outcomes require collaborations that leverage expertise, insights, and capabilities across organizations.
- Where Are They Now? Ironwood Pharmaceuticals
- How Cidara Got Its Molecule Back
- Now Is The Time For Philanthropic Venture Capital
- AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development
- Why Job Rotations Are Critical To Shaping Tomorrow's Leaders
- Companies To Watch: Spinogenix
- Efficiency Is The New Normal
- Leading Through Adversity: How Putting People First Drives Success
COMPANIES TO WATCH
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Companies To Watch: SpinogenixSpinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
-
![Greg_Kunst]( "Companies To Watch: Aurion Biotech")
Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
-
![Mark Litton]( "Companies To Watch: Athira Pharma")
Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
-
![Charles Hugh-Jones]( "Companies To Watch: Volastra Therapeutics")
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
WHERE ARE THEY NOW
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
-
![Steven Kelly_300CMYK]( "Where Are They Now? Carisma Therapeutics")
Where Are They Now? Carisma TherapeuticsIn three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.
-
![Rachel Haurwitz]( "Where Are They Now? Caribou Biosciences")
Where Are They Now? Caribou BiosciencesCaribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.
NEWSLETTER ARCHIVE
- 11.06.24 -- Now Is The Time For Philanthropic Venture Capital
- 11.06.24 -- Advances In Protein Engineering: From Antibody Design To Bispecific Optimization
- 11.04.24 -- AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development
- 11.01.24 -- Why Job Rotations Are Critical To Shaping Tomorrow's Leaders
- 10.31.24 -- Driving Therapeutic Innovation With Bioconjugates
SPOTLIGHT
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape.
